What if you could know, within days, whether a cancer treatment will actually work for a patient? For thousands of women diagnosed with ovarian cancer each year, that question is painfully urgent.  Cytoreductive surgery combined Platinum-based chemotherapy is still the standard first-line treatment, yet for nearly half of all patients it offers little benefit. Instead, it brings heavy side effects, delays effective care, and allows the disease to return in a more aggressive form.

Blocking a newly discovered immune pathway enables microglia to control diffuse midline glioma, laying the groundwork for a future therapeutic strategy. Researchers have identified a powerful new way to fight diffuse midline glioma (DMG), one of the most aggressive and lethal pediatric brain tumors in preclinical laboratory models. 

Cyclomics BV, a pioneer in liquid biopsy technology, announces the successful closing of a new investment round led by Myosotis Investments and supported by Oncode Bridge Fund. This capital infusion marks a pivotal transition for the company as it expands its commercial operations to bring innovative diagnostic products to cancer patients.

Researchers at Oncode Institute and Princess Máxima Center have developed a new human model of the brainstem that is changing how one of the most aggressive childhood brain cancers can be studied. 

Gisteren hebben KiKa en Oncode Institute een overeenkomst getekend om de komende jaren intensief samen te werken op het gebied van kinderkankeronderzoek.

Oncode Institute accelerates the path from fundamental discovery to patient impact by supporting clinical proof of concept projects that turn scientific insights into diagnostics and therapies.

MRM Health has entered into a strategic research collaboration with Oncode Institute and the Netherlands Cancer Institute (NKI) to accelerate the development of microbiome-based therapies that enhance the effectiveness of cancer immunotherapy. 

Researchers have discovered a way to extend the effectiveness of hormone therapy using a safe, inexpensive, and widely used class of drugs: corticosteroids. The new findings, published in Nature, pave the way for a clinical study starting in 2026.

It started with an unexpected e-mail. An US biotech company working on immunotherapies had picked up a strange signal: an protein appeared to bind to LAIR-1, a receptor that dampens immune cells. But why this was happening remained unclear. 

In a lab at the Netherlands’ UMC Utrecht, researcher Madelon Maurice was chasing a fundamental question: could the cell’s own machinery be harnessed to degrade, rather than merely inhibit, disease-causing proteins on the cell surface? What at first was basic science soon revealed itself as a radical new path in drug discovery.

The new research programme SPARC has been awarded a prestigious NWO Perspectief grant. This national funding supports large collaborations between researchers and industry to create innovations with real impact on society.

Every year, hundreds of participants cycle up Alpe d’Huez to raise funds for cancer research. 
For Oncode Institute, Alpe d'HuZes is more than a challenge — it’s a symbol of community, perseverance, and purpose.

As the year draws to a close, the Oncode community once again gathered at the iconic Royal Tropical Institute in Amsterdam for two days of science, inspiration, and connection.

During the Dutch Life Sciences Conference, Myriagon was announced as the winner of the Venture Challenge Fall 2025.

Researchers have discovered a potent group of T cells that physically cling to tumour cells. The study, led by Oncode Investigator Daniel Peeper and published in Nature, opens a new direction for improving immunotherapy.

Oncode Researchers develop a faster, more flexible way to find new medicines - no DNA tags required.